Search results

  1. forestglip

    Trial Report Plasma cell targeting with the anti-CD38 antibody daratumumab in ME/CFS -a clinical pilot study, 2025, Fluge et al

    Ah, sorry. I didn't realize you were comparing to responders in the Rituximab study. I think there might be some statistical issues with comparing averages of responders only. One way to think of it is, imagine both studies have a small number of individuals with a huge step count increase of...
  2. forestglip

    Trial Report Plasma cell targeting with the anti-CD38 antibody daratumumab in ME/CFS -a clinical pilot study, 2025, Fluge et al

    If we're talking about averages, it has to be about the whole group. Otherwise, it would be cherrypicking - the same as if we found one person in the Rituximab study with a 5000 step count increase, called them a responder, and were comparing to that. From Dara trial: So average increase of...
  3. forestglip

    Utility of Glucagon-Like-Peptide-1-Receptor Agonists in Mast Cell Activation Syndrome, 2025, Lawrence B. Afrin M.D, Blitsheyn et al

    It was a claim by Lawrence Afrin in one of his books. See this post: https://www.s4me.info/threads/mast-cell-activation-syndrome-mcas-discussion-thread.16483/post-666242
  4. forestglip

    Advancing regulatory variant effect prediction with AlphaGenome 2026 Avsec et al

    If you're wondering about the AlphaGenome scores for this variant, it's pretty much the same as other indels in the area, in terms of high scores (though with some sign flips). Edit: This is from the excel file in this post...
  5. forestglip

    Still to open Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

    I think Nath is following a T cell exhaustion-type idea, where there is some sort of antigen that the immune system can't clear. It seems that inhibiting PD-1 increases immune response.
  6. forestglip

    Still to open Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

    Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) Brief Summary Background: SARS-CoV-2 is the virus that causes COVID-19.Some people who recover from an acute COVID-19 infection may continue to have symptoms that persist for...
  7. forestglip

    The New Yorker: Did a Celebrated Researcher Obscure a Baby’s Poisoning?

    For people who have access to the full original article, is the Expression of Concern actually mentioned on that page? I can only view the abstract, but I would think the Expression of Concern should show up for everyone. I don't see any mention of a 2008 Letter to the Editor about the case...
  8. forestglip

    The New Yorker: Did a Celebrated Researcher Obscure a Baby’s Poisoning?

    Looks like the New Yorker article led to some action. Retraction Watch: Lancet flags long-scrutinized report of infant poisoned by opioids in breast milk The Lancet: Expression of Concern: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother Edit...
  9. forestglip

    Still to open [Houston, Texas, USA] Effect of Metabolic Modulation on a Post-acute COVID-19 Vaccination Syndrome (PACVS) Cohort (ViTAL-SCAN19)

    The paper says enrollment requires ME/CFS criteria, though I don't see that in the ClinicalTrials.gov registration yet. From Wikipedia:
  10. forestglip

    Still to open [Houston, Texas, USA] Effect of Metabolic Modulation on a Post-acute COVID-19 Vaccination Syndrome (PACVS) Cohort (ViTAL-SCAN19)

    Protocol Paper: Effectiveness of metabolic modulation in treating post-vaccination syndrome: study protocol for a prospective and randomized controlled trial Halma, Matthew; Varon, Joseph Background Post-acute COVID-19 vaccination syndrome (PACVS) emerged as a rare complication of the...
  11. forestglip

    Still to open [Houston, Texas, USA] Effect of Metabolic Modulation on a Post-acute COVID-19 Vaccination Syndrome (PACVS) Cohort (ViTAL-SCAN19)

    Effect of Metabolic Modulation on a Post-acute COVID-19 Vaccination Syndrome (PACVS) Cohort (ViTAL-SCAN19) Brief Summary The goal of this clinical trial is to evaluate whether metabolic modulation with a combined nutraceutical product can improve symptoms and metabolic health in adults...
  12. forestglip

    Chronic Lyme disease, post-treatment Lyme disease syndrome (PTLDS)

    Yeah, I'm not sure if this is only based on his own word. NIH, at least, denied it:
  13. forestglip

    Chronic Lyme disease, post-treatment Lyme disease syndrome (PTLDS)

    Maybe I should have put "bad science" in quotes to indicate that it was McSweegan's claim. I have no knowledge of the Lyme Disease Foundation or what kind of science they do. I just thought the story of how he stopped getting work so he started writing books on NIH time was interesting.
  14. forestglip

    Chronic Lyme disease, post-treatment Lyme disease syndrome (PTLDS)

    Just the story is interesting. That he called out the Lyme Disease Foundation for bad science, and the NIH appeared to make him stop doing any important work because of that.
  15. forestglip

    Advancing regulatory variant effect prediction with AlphaGenome 2026 Avsec et al

    Can you give a simpler explanation for what you're doing? No idea what I'm looking at on the linked pages.
  16. forestglip

    Advancing regulatory variant effect prediction with AlphaGenome 2026 Avsec et al

    Yeah, it is odd. They seem to mostly be consistent within the same tissues, but I did find a few that flip within the same tissue. Some examples below. Again based on chr20:48935095:C>CTCTTTTTT and ZNFX1. I see that at least for cerebellum and frontal cortex, there's a difference in signs but...
  17. forestglip

    Advancing regulatory variant effect prediction with AlphaGenome 2026 Avsec et al

    The scores I posted are all for predicted brain expression, but looking at the scores across all tissues for the same variant-gene pair of chr20:48935095:C>CTCTTTTTT and ZNFX1, it's similarly high for pretty much all tissues. I attached all the predicted scores for RNAseq that include that...
  18. forestglip

    Advancing regulatory variant effect prediction with AlphaGenome 2026 Avsec et al

    Sure, they're in the first column of the tables. These are the first two: chr20:48914387:T>TA chr20:48935095:C>CTCTTTTTT
  19. forestglip

    Problems arising for pwME from additional diagnoses of MCAS, hEDS and POTS. Advocacy discussion.

    Thanks for sharing. This is one of my concerns. The diagnosis of ME/CFS felt like a lifeline to me, and I'd be very upset if I needed to go back to the far greater uncertainty I had before that point.
Back
Top Bottom